Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Becton, Dickinson and Company (BDX) is a global leader in medical technology, specializing in the development and manufacturing of medical devices, instrument systems, and reagents. The company operates in over 50 countries, with a strong presence in North America and Europe, and its product portfolio includes critical items such as syringes, needles, and diagnostic instruments that are essential for healthcare providers.
BDX generates revenue primarily through the sale of medical devices and diagnostic products, leveraging its extensive distribution network and established relationships with healthcare providers. The company benefits from strong pricing power due to its reputation for quality and innovation, particularly in high-demand areas such as diabetes care and infection prevention.
Regulatory approvals for new medical devices
Changes in healthcare spending and reimbursement policies
Market share shifts in diabetes care products
Global health crises impacting demand for medical supplies
Regulatory changes impacting product approvals and market access
Technological disruption from emerging competitors in medical technology
Intense competition from other medical device manufacturers
Potential for price erosion in commoditized product categories
Moderate debt levels could become a concern if interest rates rise significantly
Pension obligations may impact cash flow if not managed effectively
moderate - BDX's performance is somewhat linked to GDP growth as healthcare spending tends to rise in stronger economic conditions, but it also benefits from consistent demand regardless of economic cycles.
Interest rates affect BDX primarily through financing costs for capital expenditures and potential impacts on consumer spending in healthcare. Higher rates could compress margins if borrowing costs rise significantly.
minimal - BDX has a manageable debt-to-equity ratio of 0.72, indicating that it is not heavily reliant on credit markets.
value - BDX offers a stable dividend and a reasonable valuation relative to its cash flow generation.
low - BDX has historically exhibited low volatility, with a beta of approximately 0.8.
